Notice of Meeting, 9166-9167 [2024-02640]

Download as PDF ddrumheller on DSK120RN23PROD with NOTICES1 9166 Federal Register / Vol. 89, No. 28 / Friday, February 9, 2024 / Notices Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Todd Everett White, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 594–3962, todd.white@nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Program Project: Neuroscience and Substance use. Date: March 12, 2024. Time: 12:00 p.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Anne-Sophie Marie Lucie Wattiez, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 594–4642, annesophie.wattiez@nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Bioengineering, Surgery, Anesthesiology, and Trauma. Date: March 13, 2024. Time: 10:00 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Donald Scott Wright, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5108, MSC 7854, Bethesda, MD 20892, (301) 435– 8363, wrightds@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Fellowships: Epidemiology and Population Sciences. Date: March 13–14, 2024. Time: 10:00 a.m. to 8:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Rebecca I. Tinker, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20817, (301) 435–0637, tinkerri@csr.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS) Dated: February 6, 2024. Lauren A. Fleck, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2024–02696 Filed 2–8–24; 8:45 am] 17:20 Feb 08, 2024 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Substance Abuse and Mental Health Services Administration National Eye Institute; Notice of Closed Meetings Notice of Meeting Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Eye Institute Special Emphasis Panel; BRAIN Initiative: New Concepts and Early-Stage Research for Recording and Modulation in the Nervous System (R21). Date: March 19, 2024. Time: 10:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Eye Institute, 6700 Rockledge Dr., Bethesda, MD 20817. Contact Person: Brian Hoshaw, Ph.D., Designated Federal Official, Division of Extramural Research, National Eye Institute, National Institutes of Health, 6700 B Rockledge Dr., Rockville, MD 20892, 301– 451–2020, hoshawb@mail.nih.gov. Name of Committee: National Eye Institute Special Emphasis Panel; Conference Grant Applications (R13). Date: April 15, 2024. Time: 10:00 a.m. to 2:00 p.m. Agenda: To review and evaluate grant applications. Place: National Eye Institute, 6700 Rockledge Dr., Bethesda, MD 20817. Contact Person: Jeanette M. Hosseini, Ph.D., Scientific Review Officer, Division of Extramural Research, National Eye Institute, National Institutes of Health, 6700 B Rockledge Drive, Bethesda, MD 20892, 301– 451–2020, jeanetteh@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program No. 93.867, Vision Research, National Institutes of Health, HHS) Dated: February 5, 2024. Lauren A. Fleck, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2024–02653 Filed 2–8–24; 8:45 am] BILLING CODE 4140–01–P BILLING CODE 4140–01–P VerDate Sep<11>2014 DEPARTMENT OF HEALTH AND HUMAN SERVICES Jkt 262001 PO 00000 Frm 00054 Fmt 4703 Sfmt 4703 Pursuant to Public Law 92–463, notice is hereby given that the Substance Abuse and Mental Health Services Administration’s (SAMHSA) Center for Substance Abuse Prevention’s (CSAP) Drug Testing Advisory Board (DTAB) will convene via web conference on March 5, 2024, from 10 a.m. EST to 12:45 p.m. EST. The board will meet in open-session March 5, 2024, from 10 a.m. EST to 12:45 p.m. EST to hear presentations regarding proposed changes to the analyte table including fentanyl prevalence, fentanyl immunoassay updates, cost and benefits analysis and a summary of public comments received regarding the proposed changes to the HHS Drug Testing Panels. Section 8105 of the Fighting Opioid Abuse in Transportation Act, included in the SUPPORT for Patients and Communities Act, required the Secretary to determine whether it is justified, based on the reliability and cost-effectiveness of testing, to revise the Mandatory Guidelines for Federal Workplace Drug Testing Programs to include fentanyl. Section 8105 additionally required the Secretary to consider whether to include any other drugs or other substances listed in Schedule I and II of Controlled Substances Act (CSA). Norfentanyl is a metabolite of fentanyl. Because it is also an immediate precursor used in the illicit manufacture of fentanyl, it is a Schedule II substance under the CSA. Fentanyl is involved in a large proportion of overdose deaths in the United States and is therefore an important public safety concern. Furthermore, fentanyl is increasingly used as a stand-alone substance, not in conjunction with heroin and other substances. According to the National Forensic Laboratory Information System (NFLIS) 2022 report, fentanyl was the 3rd most frequently identified drug and accounted for 13.81% of all drugs reported by forensic laboratories.1 Norfentanyl is an important component of identifying people who use fentanyl when urine is the specimen matrix. Fentanyl has been detected in oral fluid in patients receiving pain management 1 National Forensic Laboratory Information System (NFLIS). (2022). NFLIS-Drug 2022 Annual Report. U.S. Department of Justice, Drug Enforcement Agency, Diversion Control Division. 2022 NFLIS-Drug Annual Report.pdf. E:\FR\FM\09FEN1.SGM 09FEN1 Federal Register / Vol. 89, No. 28 / Friday, February 9, 2024 / Notices ddrumheller on DSK120RN23PROD with NOTICES1 services, overdose cases, and driving under the influence of drugs (DUID) cases. Information provided by HHScertified laboratories in 2023 indicated that a majority (84%) of the laboratories analyzed non-regulated workplace specimens for fentanyl and/or norfentanyl, and that all had the ability to analyze urine specimens for fentanyl with sufficiently sensitive detection limits using commercially available immunoassay kits and confirmatory test instrumentation commonly used in HHS-certified laboratories. Proposed addition to HHS Drug Testing Panels as listed below: Urine analyte Initial test cutoff Fentanyl ......... Norfentanyl .... 1 ng/mL .... ................... Oral fluid analyte Initial test cutoff Fentanyl ......... 1 ng/mL .... Confirmation cutoff 1.0 ng/mL. 1.0 ng/mL. Confirmation cutoff 1.0 ng/mL. The Department plans to remove MDA and methylenedioxymethamphetamine (MDMA) from the drug testing panel, because the number of positive specimens reported by HHScertified laboratories does not support testing all specimens for MDA and MDMA in Federal workplace drug testing programs. Information provided to the Department through the NLCP in 2021 and 2022 shows the positivity rate for MDMA ranges from 0.001 to 0.003%, and a review of the results indicate that >25% of the positive specimens are likely agency blind samples. MDA has a lower positivity rate than MDMA and both have lower positivity rates than phencyclidine (PCP). SAMHSA also considered removing PCP but decided against this change. While PCP has an overall positivity rate nearly as low as MDMA, there are regional differences in positivity, with some areas of the country having much higher rates, so PCP remains a regulated test analyte. Because MDA and MDMA are Schedule I drugs, a Federal agency may test specimens for these analytes in accordance with Section 3.2 of the UrMG and OFMG (i.e., on a case-by-case basis for reasonable suspicion or postaccident testing, or routinely with a waiver from the Secretary). Meeting registration information can be completed at https://snacregister. samhsa.gov/. Web conference and call information will be sent after completing registration. Meeting information and a roster of DTAB members may be obtained by accessing the SAMHSA Advisory Committees VerDate Sep<11>2014 18:36 Feb 08, 2024 Jkt 262001 website, https://www.samhsa.gov/ about-us/advisory-councils/meetings, or by contacting the Designated Federal Officer, Lisa Davis. Committee Name: Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Prevention, Drug Testing Advisory Board. Dates/Time/Type: March 5, 2024, from 10:00 a.m. EST to 12:45 p.m. EST: OPEN. Place: Virtual. To Submit Comments: Requests to make public comment during the public comment period of the March DTAB meeting must be made in writing at least 7 days prior to the meeting to the following email: DFWP@ samhsa.hhs.gov. Contact: Lisa S. Davis, M.S, Social Science Analyst, Center for Substance Abuse Prevention, 5600 Fishers Lane, Rockville, Maryland 20857, Telephone: (240) 276–1440, Email: Lisa.Davis@ samhsa.hhs.gov. Anastasia Flanagan, Public Health Advisor, Division of Workplace Programs. [FR Doc. 2024–02640 Filed 2–8–24; 8:45 am] BILLING CODE 4162–20–P DEPARTMENT OF HOMELAND SECURITY Federal Emergency Management Agency [Docket ID: FEMA–2024–0006; OMB No. 1660–0110] Agency Information Collection Activities: Proposed Collection; Comment Request; Nonprofit Security Grant Program (NSGP) Investment Justification & NSGP Prioritization Tracker Federal Emergency Management Agency, Department of Homeland Security. ACTION: 60-Day notice of extension and request for comments. AGENCY: The Federal Emergency Management Agency (FEMA), as part of its continuing effort to reduce paperwork and respondent burden, invites the general public to take this opportunity to comment on an extension of a currently approved information collection. In accordance with the Paperwork Reduction Act of 1995, this notice seeks comments concerning the Nonprofit Security Grant Program (NSGP). The NSGP provides funding support for security-related enhancements to nonprofit SUMMARY: PO 00000 Frm 00055 Fmt 4703 Sfmt 4703 9167 organizations that are at high risk of a terrorist or other extremist attack. Comments must be submitted on or before April 9, 2024. DATES: ADDRESSES: To avoid duplicate submissions to the docket, please submit comments at www.regulations.gov under Docket ID FEMA–2024–0006. Follow the instructions for submitting comments. All submissions received must include the agency name and Docket ID. Regardless of the method used for submitting comments or material, all submissions will be posted, without change, to the Federal eRulemaking Portal at https://www.regulations.gov, and will include any personal information you provide. Therefore, submitting this information makes it public. You may wish to read the Privacy Act notice that is available via the link in the footer of www.regulations.gov. FOR FURTHER INFORMATION CONTACT: Mark Silveira, Branch Chief, FEMA Grant Programs Directorate, Preparedness Grants Program, 202–786– 9598 mark.silveira@fema.dhs.gov. You may contact the Information Management Division for copies of the proposed collection of information at email address: FEMA-InformationCollections-Management@fema.dhs.gov. The collection of information for the Nonprofit Security Grant Program is mandated by sections 2003 and 2004 of the Homeland Security Act of 2002 (6 U.S.C. 604), as amended by section 101, Title I of the Implementing Recommendations of the 9/11 Commission Act of 2007 (Pub. L. 110– 053). These sections mandate that applicants submit plans to describe the proposed division of responsibilities and distribution of funding among the local and tribal government in the highrisk urban area; mandate that applicants submit information in support of the application as the Administrator may reasonably require; mandate that applicants submit their application to each State for review before submission of such application to the Department; and delineate and describe the actions Governors must take if deeming that an application is inconsistent with their States’ Homeland Security Strategy. This program is designed to promote coordination and collaboration in emergency preparedness activities among public and private community representatives, State, and local government agencies. SUPPLEMENTARY INFORMATION: E:\FR\FM\09FEN1.SGM 09FEN1

Agencies

[Federal Register Volume 89, Number 28 (Friday, February 9, 2024)]
[Notices]
[Pages 9166-9167]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-02640]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration


Notice of Meeting

    Pursuant to Public Law 92-463, notice is hereby given that the 
Substance Abuse and Mental Health Services Administration's (SAMHSA) 
Center for Substance Abuse Prevention's (CSAP) Drug Testing Advisory 
Board (DTAB) will convene via web conference on March 5, 2024, from 10 
a.m. EST to 12:45 p.m. EST.
    The board will meet in open-session March 5, 2024, from 10 a.m. EST 
to 12:45 p.m. EST to hear presentations regarding proposed changes to 
the analyte table including fentanyl prevalence, fentanyl immunoassay 
updates, cost and benefits analysis and a summary of public comments 
received regarding the proposed changes to the HHS Drug Testing Panels.
    Section 8105 of the Fighting Opioid Abuse in Transportation Act, 
included in the SUPPORT for Patients and Communities Act, required the 
Secretary to determine whether it is justified, based on the 
reliability and cost-effectiveness of testing, to revise the Mandatory 
Guidelines for Federal Workplace Drug Testing Programs to include 
fentanyl. Section 8105 additionally required the Secretary to consider 
whether to include any other drugs or other substances listed in 
Schedule I and II of Controlled Substances Act (CSA). Norfentanyl is a 
metabolite of fentanyl. Because it is also an immediate precursor used 
in the illicit manufacture of fentanyl, it is a Schedule II substance 
under the CSA.
    Fentanyl is involved in a large proportion of overdose deaths in 
the United States and is therefore an important public safety concern. 
Furthermore, fentanyl is increasingly used as a stand-alone substance, 
not in conjunction with heroin and other substances. According to the 
National Forensic Laboratory Information System (NFLIS) 2022 report, 
fentanyl was the 3rd most frequently identified drug and accounted for 
13.81% of all drugs reported by forensic laboratories.\1\ Norfentanyl 
is an important component of identifying people who use fentanyl when 
urine is the specimen matrix. Fentanyl has been detected in oral fluid 
in patients receiving pain management

[[Page 9167]]

services, overdose cases, and driving under the influence of drugs 
(DUID) cases. Information provided by HHS-certified laboratories in 
2023 indicated that a majority (84%) of the laboratories analyzed non-
regulated workplace specimens for fentanyl and/or norfentanyl, and that 
all had the ability to analyze urine specimens for fentanyl with 
sufficiently sensitive detection limits using commercially available 
immunoassay kits and confirmatory test instrumentation commonly used in 
HHS-certified laboratories.
---------------------------------------------------------------------------

    \1\ National Forensic Laboratory Information System (NFLIS). 
(2022). NFLIS-Drug 2022 Annual Report. U.S. Department of Justice, 
Drug Enforcement Agency, Diversion Control Division. 2022 NFLIS-Drug 
Annual Report.pdf.
---------------------------------------------------------------------------

    Proposed addition to HHS Drug Testing Panels as listed below:

------------------------------------------------------------------------
                                    Initial test
         Urine analyte                 cutoff        Confirmation cutoff
------------------------------------------------------------------------
Fentanyl.......................  1 ng/mL..........  1.0 ng/mL.
Norfentanyl....................  .................  1.0 ng/mL.
------------------------------------------------------------------------


------------------------------------------------------------------------
                                    Initial test
       Oral fluid analyte              cutoff        Confirmation cutoff
------------------------------------------------------------------------
Fentanyl.......................  1 ng/mL..........  1.0 ng/mL.
------------------------------------------------------------------------

    The Department plans to remove MDA and methylenedioxy- 
methamphetamine (MDMA) from the drug testing panel, because the number 
of positive specimens reported by HHS-certified laboratories does not 
support testing all specimens for MDA and MDMA in Federal workplace 
drug testing programs. Information provided to the Department through 
the NLCP in 2021 and 2022 shows the positivity rate for MDMA ranges 
from 0.001 to 0.003%, and a review of the results indicate that >25% of 
the positive specimens are likely agency blind samples. MDA has a lower 
positivity rate than MDMA and both have lower positivity rates than 
phencyclidine (PCP). SAMHSA also considered removing PCP but decided 
against this change. While PCP has an overall positivity rate nearly as 
low as MDMA, there are regional differences in positivity, with some 
areas of the country having much higher rates, so PCP remains a 
regulated test analyte. Because MDA and MDMA are Schedule I drugs, a 
Federal agency may test specimens for these analytes in accordance with 
Section 3.2 of the UrMG and OFMG (i.e., on a case-by-case basis for 
reasonable suspicion or post-accident testing, or routinely with a 
waiver from the Secretary).
    Meeting registration information can be completed at https://snacregister.samhsa.gov/. Web conference and call information will be 
sent after completing registration. Meeting information and a roster of 
DTAB members may be obtained by accessing the SAMHSA Advisory 
Committees website, https://www.samhsa.gov/about-us/advisory-councils/meetings, or by contacting the Designated Federal Officer, Lisa Davis.
    Committee Name: Substance Abuse and Mental Health Services 
Administration, Center for Substance Abuse Prevention, Drug Testing 
Advisory Board.
    Dates/Time/Type: March 5, 2024, from 10:00 a.m. EST to 12:45 p.m. 
EST: OPEN.
    Place: Virtual.
    To Submit Comments: Requests to make public comment during the 
public comment period of the March DTAB meeting must be made in writing 
at least 7 days prior to the meeting to the following email: 
[email protected].
    Contact: Lisa S. Davis, M.S, Social Science Analyst, Center for 
Substance Abuse Prevention, 5600 Fishers Lane, Rockville, Maryland 
20857, Telephone: (240) 276-1440, Email: [email protected].

Anastasia Flanagan,
Public Health Advisor, Division of Workplace Programs.
[FR Doc. 2024-02640 Filed 2-8-24; 8:45 am]
BILLING CODE 4162-20-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.